Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$41.99 - $62.38 $253,451 - $376,525
-6,036 Reduced 28.87%
14,869 $873,000
Q3 2023

Nov 14, 2023

BUY
$27.8 - $45.35 $581,159 - $948,041
20,905 New
20,905 $910,000
Q1 2023

May 15, 2023

BUY
$36.54 - $54.26 $2.08 Million - $3.09 Million
56,929 Added 557.96%
67,132 $2.5 Million
Q4 2022

Feb 14, 2023

BUY
$41.27 - $98.62 $102,308 - $244,478
2,479 Added 32.09%
10,203 $462,000
Q3 2022

Nov 14, 2022

SELL
$59.5 - $86.7 $864,892 - $1.26 Million
-14,536 Reduced 65.3%
7,724 $539,000
Q2 2022

Aug 15, 2022

SELL
$39.16 - $88.71 $138,352 - $313,412
-3,533 Reduced 13.7%
22,260 $1.49 Million
Q1 2022

May 16, 2022

BUY
$75.82 - $150.97 $1.37 Million - $2.73 Million
18,050 Added 233.11%
25,793 $2.12 Million
Q4 2021

Feb 14, 2022

SELL
$132.01 - $190.29 $894,103 - $1.29 Million
-6,773 Reduced 46.66%
7,743 $1.14 Million
Q3 2021

Nov 15, 2021

SELL
$132.13 - $177.45 $5.07 Million - $6.81 Million
-38,370 Reduced 72.55%
14,516 $2.57 Million
Q2 2021

Aug 16, 2021

BUY
$144.0 - $179.73 $5.72 Million - $7.14 Million
39,715 Added 301.53%
52,886 $8.54 Million
Q1 2021

May 17, 2021

BUY
$158.92 - $221.61 $499,962 - $697,185
3,146 Added 31.38%
13,171 $2.26 Million
Q4 2020

Feb 16, 2021

BUY
$162.05 - $240.27 $506,082 - $750,363
3,123 Added 45.25%
10,025 $2.2 Million
Q3 2020

Nov 16, 2020

BUY
$113.26 - $167.27 $395,617 - $584,274
3,493 Added 102.46%
6,902 $1.15 Million
Q2 2020

Aug 14, 2020

BUY
$72.01 - $120.39 $245,482 - $410,409
3,409 New
3,409 $389,000
Q1 2020

May 15, 2020

SELL
$69.78 - $116.21 $774,558 - $1.29 Million
-11,100 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$70.76 - $128.86 $765,198 - $1.39 Million
10,814 Added 3781.12%
11,100 $1.43 Million
Q3 2019

Nov 14, 2019

SELL
$77.91 - $109.6 $1.62 Million - $2.28 Million
-20,781 Reduced 98.64%
286 $22,000
Q2 2019

Aug 14, 2019

BUY
$59.49 - $104.71 $1.25 Million - $2.21 Million
21,067 New
21,067 $2.17 Million
Q4 2018

Feb 14, 2019

SELL
$32.0 - $47.43 $3,200 - $4,743
-100 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$47.1 - $62.7 $4,710 - $6,270
100 New
100 $5,000
Q2 2018

Aug 14, 2018

SELL
$26.05 - $52.4 $164,167 - $330,224
-6,302 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$17.2 - $34.95 $108,394 - $220,254
6,302 New
6,302 $193,000

Others Institutions Holding MRTX

About Mirati Therapeutics, Inc.


  • Ticker MRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,609,800
  • Description
  • Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...
More about MRTX
Track This Portfolio

Track Cubist Systematic Strategies, LLC Portfolio

Follow Cubist Systematic Strategies, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.